tiprankstipranks
Sangamo Therapeutics (DE:GBY)
MUNICH:GBY
Germany Market

Sangamo Therapeutics (GBY) Stock Forecast & Price Target

4 Followers
See the Price Targets and Ratings of:

GBY Analyst Ratings

Currently, no data available
Based on NaN analysts giving stock ratings to
Sangamo
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

GBY Stock 12 Month Forecast

There Are No Analyst Ratings for DE:GBY In The Last 3 Months.
Highest Price TargetAverage Price TargetLowest Price Target
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

GBY Financial Forecast

GBY Earnings Forecast

Currently, no earnings data available.
Currently, no earnings data available.

GBY Sales Forecast

The previous quarter’s earnings for GBY were €93.46K.
The previous quarter’s earnings for GBY were €93.46K.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
RBC Capital Analyst forecast on DE:GBY
RBC Capital
RBC Capital
€1.71
Hold
2348.28%
Upside
Reiterated
05/14/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Aquestive Therapeutics (NASDAQ: AQST), Sangamo Therapeutics (Other OTC: SGMO) and Insight Molecular Diagnostics (NASDAQ: IMDX)
Wells Fargo Analyst forecast on DE:GBY
Unknown Analyst
Wells Fargo
Not Ranked
Wells Fargo
€3.43€1.71
Hold
2348.28%
Upside
Reiterated
01/05/26
Sangamo Biosciences (SGMO) Receives a Hold from Wells Fargo
Barclays Analyst forecast on DE:GBY
Barclays
Barclays
€4.28€0.86
Hold
1124.14%
Upside
Downgraded
11/07/25
Sangamo Biosciences (SGMO) was downgraded to a Hold Rating at Barclays
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
RBC Capital Analyst forecast on DE:GBY
RBC Capital
RBC Capital
€1.71
Hold
2348.28%
Upside
Reiterated
05/14/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Aquestive Therapeutics (NASDAQ: AQST), Sangamo Therapeutics (Other OTC: SGMO) and Insight Molecular Diagnostics (NASDAQ: IMDX)
Wells Fargo Analyst forecast on DE:GBY
Unknown Analyst
Wells Fargo
Not Ranked
Wells Fargo
€3.43€1.71
Hold
2348.28%
Upside
Reiterated
01/05/26
Sangamo Biosciences (SGMO) Receives a Hold from Wells Fargo
Barclays Analyst forecast on DE:GBY
Barclays
Barclays
€4.28€0.86
Hold
1124.14%
Upside
Downgraded
11/07/25
Sangamo Biosciences (SGMO) was downgraded to a Hold Rating at Barclays
Stocks with the Highest Top Analyst Consensus in the General Sector
STDNStandard Nuclear
SKHYSK Hynix
ITGITG Inc. Class A
LIMENeutron Holdings, Inc.
EROCERock
Find stocks in the General sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Sangamo Therapeutics

3 Months
Google BiotechnologyTipRanks - Google
Success Rate
2/2 ratings generated profit
100%
Average Return
+21.20%
Copying Google Biotechnology's trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +21.20% per trade.
1 Year
Google BiotechnologyTipRanks - Google
Success Rate
2/2 ratings generated profit
100%
Average Return
+21.20%
Copying Google Biotechnology's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +21.20% per trade.
2 Years
Google BiotechnologyTipRanks - Google
Success Rate
2/2 ratings generated profit
100%
Average Return
+21.20%
Copying Google Biotechnology's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +21.20% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

GBY Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
4
4
3
1
0
Buy
0
0
0
0
0
Hold
1
2
3
3
2
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
5
6
6
4
2
In the current month, GBY has received 0 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. GBY average Analyst price target in the past 3 months is .
Each month's total comprises the sum of three months' worth of ratings.

GBY Stock Forecast FAQ

What is DE:GBY’s average 12-month price target, according to analysts?
Currently, no data Available
What is DE:GBY’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for DE:GBY, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
    How can I follow the stock ratings of top Wall Street analysts?
    Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
      Is Sangamo Therapeutics a Buy, Sell or Hold?
      Currently, no data Available
      What is Sangamo Therapeutics’s share price target?
      Currently, no data Available
      What do analysts say about Sangamo Therapeutics?
      Not enough analysts have published a price target to provide an average price target.
      How can I buy shares of Sangamo Therapeutics?
      To buy shares of DE:GBY, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.